Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a promising clinical-stage biotechnology company with a strong focus on developing treatments for age-related neurologic disorders. Positive data from preclinical and clinical trials, indicating the potential of their product candidate Neflamapimod to improve synaptic dysfunction, supports the outlook for the company. Upcoming catalysts, such as additional data presentations and the initiation of a Phase 3 trial, could further solidify the company's position and potential for success in the market. However, there are potential risks involved, such as clinical/regulatory and partnership/financial risks, that investors should keep in mind as the company advances towards pivotal development.

Bears say

CervoMed is facing potential setbacks in their development of Neflamapimod as their pivotal trial for DLB may not complete enrollment until the end of 2027, with top-line data release in 2H28. Their current valuation and price target of $25 is based on a discounted cash flow methodology using a 12% discount rate and a 3% terminal rate. However, there are various risks that could impact their success, such as delays in trial initiation or failure to secure regulatory approval. These factors contribute to a negative outlook on the stock.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.